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ABSTRACT
The menopausal transition or perimenopause is associated with numerous symptoms. Women
entering perimonopause normally have menstrual irregular periods due to an imbalance of serum
estradiol. Since the status of estrogen is known as an important determinant of bone mass
density, menopausal symptoms can be an effective indicator of bone status in women. This
study aimed to evaluate the relationship between perimenopause symptoms and bone mineral
density (BMD). This was an observational study using cross-sectional design conducted during
three months periode from June to August 2010 in Kalangan Village, Banguntapan, Bantul
District. Subjects were women between the aged 46-55 years who fulfilled the inclusion and
exclusion criteria. After underwent history taking, subjects underwent physical examination
according to International Physical Activity Questionnaires (IPAQ). The BMD of subjects was
than measured using dual-energy X-ray absorptiometry (DEXA). The relationship between
perimenopause symptoms and BMD was then evaluated using multivariate analysis. The results
showed that perimenopause symptoms increase abnormal BMD of subjects 1.38 times higher
than those without perimenopause symptoms (RR=1.38; 95%CI 1.39-13.78; p=0.01). In
conclusion, the perimenopause symptoms is associated with the high proportion of abnormal
BMD in women.
ABSTRAK
Transisi menopause atau perimenopause dikaitkan dengan banyak gejala. Wanita yang memasuki
perimenopause biasanya mengalami ketidakteraturan menstruasi karena ketidakseimbangan
estradiol serum. Oleh karena status estrogen diketahui penting dalam menentukan densitas
masa tulang, gejala menopause dapat menjadi indikator efektif status tulang pada wanita.
Penelitian ini bertujuan untuk mengkaji hubungan antara gejala menopause dan densitas mineral
tulang (DMT). Penelitian ini merupakan penelitian observasional dengan rancangan potong lintang
yang dilakukan selama tiga bulan antara Juni sampai Agustus 2014 di Desa Kalangan, Banguntapan,
Kabupaten Bantul. Subyek penelitian adalah wanita berumur 46-55 tahun yang memenuhi kriteria
inklusi dan eksklusi. Setelah ditanyakan riwayat kesehatannya, subyek menjalanai pemeriksaan
fisik menurut International Physical Activity Questionnaires (IPAQ). Densitas mineral tulang
subyek kemudian ditetapkan dengan dual-energy X-ray absorptiometry (DEXA). Hubungan antara
gejala perimenopause dan DMT dikaji menggunakan analisis multivariat. Hasil penelitian
menunjukkan gejala perimenopause meningkatkan DMT abnormal 1,38 lebih tinggi pada wanita
dengan gejala perimenopause dibandingkan wanita tanpa gejala perimenopause (RR=1,38; 95%CI
1,39-13,78; p=0,01). Dapat disimpulkan bahwa gejala perimenopause berhubungan dengan
tingginya DMT abnormal pada wanita.
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INTRODUCTION
The menopausal transition or perimenou-
pause is associated with numerous symptoms.
Women entering perimenopause normally have
menstrual irregular periods during 2 to 7 years
before menopause due to an imbalance of serum
estradiol. The decline in ovarian function is
considered as a major factor in the development
and manifestation of symptoms of menopause,
as it can happen rapidly in some women and
slower in others. Some women produce
sufficient endogenous estrogen to remain
without symptoms, while others show a variety
of symptoms during climacterium.1-3
Since the status of estrogen is known as an
important determinant of bone mass density,
menopausal symptoms can be an effective
indicator of bone status in women. Peri-and
post-menopausal women show that hot flushes
are significant and independent determinants of
bone loss in radius.4 The radial bone loss as
high as 9% per year occurs in women who
reported symptoms, compared with no
symptoms women. This evidence suggests that
disturbances in ovarian function can adversely
impact bone mass and increased the risk of
osteoporosis.5
To diagnose osteoporosis before the
occurrence of fracture, examination that assesses
bonedensity isnecessary.Currentexaminationwith
the most accurate, and relatively safe, fast and
painless is using the dual-energy X-ray
absorptiometry (DEXA).Thepurposeof this study
is toknowtheproportionofabnormalbonemineral
density (BMD) in women with and without
perimenopause symptoms. It is important to find
other alternative methods, such as perimenopause
symptoms in clinical findings, to determine the
decrease of bone density or abnormal BMD early
therefore perimenopausal fracture risk due to
osteopenia or osteoporosis can be prevented.6
MATERIALS AND METHODS
Subjects
This was an observational study using
cross-sectional design conducted during three
months periode from June to August 2010 in
KalanganVillage, Banguntapan, Bantul District.
Inclusion criteria included women subjects
between the age from 46 to 55 years who
visiting Posyandu Lansia (Local Health Clinic
for the Elderly) and willing to be research
subjects. Exclusion criteria included subjects
with apparent history of diabetes mellitus,
neoplasma, rheumatoid arthritis, endocrine
disorders, fractures, consumption of corticos-
teroids, or hormonal therapy. Minimum number
of samples had been obtained from calculating
a sample size of 86 subjects. The protocol of
the study was approved by the Medical and
Health Research Ethics Committee, Faculty of
Medicine, Universitas Gadjah Mada, Yogya-
karta.
Procedure of study
Study was coducted in three stages. First
stage was history taking including presenting
complaint, past medical history and history of
taking anythings that are associated with risk
factors the illness such as age, milk and coffee
consumptions.
Second stage was physical examination
including height and weight as well as physical
activity. The physical activity was evaluated
according to International Physical Activity
Questionnaires (IPAQ).7 Furthermore, perimeno-
pause symptoms were evaluatedbased anamnesis
including hot flashes, irregular menstrual periods,
urogenitaldiscomfort andpsychological problems
as conducted by Salamone.8 Subjects reporting at
least one menopausal symptom after a break
menstrual period between 2-12 months were
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classified as perimenopause symptoms, whereas
subjects reporting no symptoms were classified
as without perimenopause symptoms.
Third stage was measurement of BMD using
DEXAin Department of Radiology, Dr. Sardjito
General Hospital. The value of BMD was used
to calculate T scores which used to evaluate
the mineral status of subject’s bone with
compared to normal women BMD according to
World Health Organization criteria.9 Women
with a T score at the 1 SD (standard deviation)
below normal women were considered as
normal BMD, a T score between 1 SD and 2.5
SD below normal women were considered as
osteopenia and a T score at the 2.5 SD or more
below normal women were considered as
osteoporosis. Subjects would be considered
abnormal BMD if they had osteopenia or
osteoporosis.
Statistical analysis
Statistical tests used in this analysis were the
multivariate with significance level of p <0.05
and confidence interval (CI) 95%. The value of
RR (risk ratio) was applied to determine the
possible relationship between the independent
variables with the dependent ones.
RESULTS
Characteristics of subjects
A total 86 subjects consisted of 60 subjects
with perimenopause symptoms and 26 subjects
without perimenopause symptoms were enrolled
in thisstudy.Thecharacteristics subjectsareshown
inTABLE 1. No significantly different in terms of
age, BMI (body mass index), physical activity,
consumption of coffee and consumption of milk
were observed from both groups of subjects (p>
0.05).
TABLE 1. Characteristics of subjects with and no perimenopause symptoms
The relationship between perimenopause
symptoms and BMD
TABLE 2 shows the relationship between
BMD of subjects and the perimenopause
symptoms. Among 54 subjects with perimeno-
pause symptoms, 42 (77.8) subjects had
abnormal BMD, whereas among 32 subjects
without perimenopause symptoms, only 12
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(22.2%) subjects had abnormal BMD. It was
indicated that the incidence of abnormal BMD
was significantly higher in subjects with
perimenopause symptoms compared to in
subjects without perimenopause symptoms
(p<0.05). Moreover, the women with perimeno-
pause symptoms may increase the risk of
abnormal BMD 0.51 times higher than those
without perimenopause symptoms (RR=0.51;
95%CI 0.27-0.96; p = 0.04).
TABLE 2. The relationship between BMD of subjects and perimenopause symptoms
The relationship between risk factors of
perimanopause symptoms and BMD
TABLE 2 shows the relatioship between
the risk factors of perimenopause symptoms and
BMD. No significantly relationship between
age, physical activity, consumption of coffee or
milk with the occurrence of abnormal BMD.
However, BMI of subjects was proven to be
the risk factor of the abnormal BMD. Women
with BMI < 18.5 kg/m2 had a 0.56 times higher
of abnormal BMD than women with >18.5 kg/
m2 (RR=0.56; 95%CI 0.41-0.77; p=0.00).
TABLE 3. The relationship between risk factors of perimenopause symptoms and BMD
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Multivariate analysis
TABLE 3 shows the multivariate analysis
of the relatioship between the risk factors of
perimenopause symptoms and BMI and the
occurrence of abnormal BMD. Perimenopause
symptoms and BMI were proven to be
independent risk factors of the occurence of
BMD. Women with perimenopause symptoms
had a 1.38 times higher of abnormal BMD than
those without perimenopause symptoms
(RR=1.38; 95%CI 1.39-13.78; p=0.01).
Furthermore, women with BMI < 18.5 kg/m2
had a 0.56 times higher of abnormal BMD than
women with > 18.5 kg/m2 (RR=0.56; 95%CI
0.03-0.39; p=0.00).
TABLE 4. Multivariate analysis between BMI and perimenopause symptoms
DISCUSSION
This study showed that there was relation-
ship between perimenopause symptoms and
abnormal BMD women. Studies concerning the
BMD in peri and postmenopausal women have
been reported by some authors. Jacka et al.10
reported that in perimenopausal women with
self-reported depression was associated with
lower BMD at the hip. Another study reported
that postmenopausal women had significantly
lower mean BMD and a higher incidence of
osteoporosis compared with the premenopausal
women. Moreover, age and a greater post-
menopausal duration showed a significant
negative association with BMD.11 The BMD
demonstrates an accelerated rate of bone loss
during the menopausal transition. The greatest
reduction occurs in the year before the final
menstrual period and the first 2 years
thereafter.12
The perimenopausal period in women is
characterized by various somatic, vasomotor,
sexual and psychological symptoms.13 Many
symptoms have been identified and associated
with perimenopause like hot flashes, hot flushes,
night sweats, irregular heart beat, mood swings,
trouble sleeping through the night, loss of libido,
vagina dryness, crashing fatigue, gastrointes-
tinal distress, difficulty concentration, mental
confusion, depression etc.4,5,13 These symptoms
are associated with a low progresteron to
estrogen ratio (estrogen dominance). In addition,
testoterone levels may also start to decline
before the last menstrual and estrogen is often
last hormone to decline.3,13
Estrogen plays an important role in the
growth and maturation of bone as well as in the
regulation of bone turnover in adult bone. The
major physiological effect of estrogen is to
inhibit bone resorption. Bone cells have two
kinds of intracellular steroid receptors for
estrogen. When estrogen binds to the receptors,
various genes become active. Estrogen also has
effects that do not depend on activating the
DNA. Estrogen effects may be mediated in part
by growth factors and interleukins (IL). For
example, IL6 is a potent stimulator of bone
resorption, and estrogen blocks the osteoblast’s
synthesis of IL 6. Estrogen may also antagonize
the IL 6 receptors.12,14
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The decline of estrogen levels during
perimenopause causes several symptoms lead
to an increase in bone resorption and reduction
in BMD. 3,15 This study found that the
perimenopause symptoms is associated with the
lower BMD in women which is suported by
others studies.10-12 Therefore, perimenopause
symptoms may can be used as BMD marker in
perimonopausal women. This clinical symptoms
will be easy to be implemented in clinical
setting. However, further study should be
performed with larger sample size to validate
the relationship between perimenopause
symptoms and BMD in women. The finding will
give benefit to take action in prevention of
perimenopause fracture risk.
CONCLUSION
In conclusion, the perimenopause symptoms
is associated with the high proportion of
abdnormal BMD in women. The proportion of
abnormal BMD in the women with
perimenopasue symptoms is higher compared
to the women without perimenopasue symptoms
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